SLU-PP-332

Compound Overview

SLU-PP-332 is not a peptide. The supplied chemistry data identifies it as a small-molecule ERR agonist, with the structural description limited to a synthetic estrogen-related receptor agonist small molecule. Because no peptide sequence, sequence display, or component list is provided, this page treats SLU-PP-332 as a sequence-free small molecule and anchors the technical identity to the supplied CAS number, molecular formula, molecular weight, classification, and intended-use language.

The Nexus product record currently lists the available presentation as an oral tablet, while the chemistry record states that the physical form may be powder or tablets per vendor specification. Because the source does not provide final tablet strength, excipients, tablet count, or SKU, no formulation-specific claim is made here. Researchers should verify the final product label, supplier documentation, and any lot-specific COA before using a received unit in a controlled laboratory workflow.

Research-context language for SLU-PP-332 is limited to the terms provided in the source record: ERR agonist small molecule, preclinical metabolic research, and exercise-mimetic research models. These phrases are included only as compound-class and research-background descriptors. They are not human-use claims, veterinary-use claims, therapeutic claims, disease claims, or dosing guidance.

Research Background & Published Literature

The supplied research background for SLU-PP-332 is concise. It states that SLU-PP-332 is a small-molecule ERR agonist used in preclinical metabolic and exercise-mimetic research models. No peer-reviewed paper titles, authors, experimental systems, concentrations, assay protocols, outcome endpoints, or citation-level summaries were provided in the source data.

The research record also warns that public records disagree on PubChem CID across vendor pages. For that reason, this Nexus description does not use a PubChem CID as the controlling identifier. The supported identifiers in this page are the supplied CAS number, molecular formula, molecular weight, and any current COA or supplier documentation available for the specific lot.

Two external source references are included in the SLU-PP-332 research record for general identity and specification context:

These references are not used here to add unsupported purity values, COA values, mechanisms beyond the supplied ERR agonist classification, therapeutic outcomes, disease-treatment language, human-use guidance, veterinary-use guidance, or dosing instructions.

Researchers reviewing the literature around this compound can use the peer-reviewed resources below for additional context on mechanism of action, signaling pathways, and controlled laboratory research applications:

• Xu et al. (2024) — Circulation
• Billon et al. (2024) — J Pharmacol Exp Ther
• Wang et al. (2023) — Am J Pathol

Storage, Handling & Stability Guidelines

The supplied storage guidance states: store per supplier COA and protect from heat, light, and moisture. Because the active Nexus catalog entry currently lists an oral tablet format while the chemistry record also references powder, laboratories should defer to the current supplier COA, final product label, and any lot-specific documentation before setting final storage procedures.

• Protect SLU-PP-332 material from unnecessary heat exposure during storage and handling.
• Protect the material from direct light unless current supplier documentation specifies a different validated condition.
• Minimize moisture exposure according to the supplier COA and the receiving laboratory's handling procedure.
• For tablet-format inventory, confirm tablet-specific storage conditions against the final product label or lot-specific documentation before use.
• For powder-format inventory, follow the supplier COA because no universal temperature condition was provided in the source record.

No reconstitution solvent, post-opening stability interval, shelf-life study, humidity tolerance, temperature-excursion range, tablet excipient list, or formulation-specific stability study was provided in the source data. Those values should not be assumed from this page.

Lab Verification

Nexus maintains research-compound verification records through the Lab Verified archive. In general terms, lab verification may include High-Performance Liquid Chromatography (HPLC) review for chromatographic profile and purity assessment, along with Mass Spectrometry (MS) review for molecular identity confirmation where lot-level documentation is available.